Loading clinical trials...
Loading clinical trials...
Recent evidence suggests that curcumin supplementation may reduce muscle inflammation, oxidative markers, and muscle damage. The most favourable dosage to elicit these ergogenic effects are yet to be established; both 750mg \& 1500mg has been shown to be effective. Curcumin supplementation has been ingested in numerous different ways however, no previous research to date has used curcumin in a hydrolysed (drinkable) format. The aim of this study is to investigate whether hydrolysed curcumin can reduce indices of muscle damage and improve recovery, whilst also examining a potential dose-response effect.
Age
18 - 35 years
Sex
ALL
Healthy Volunteers
Yes
Start Date
May 1, 2022
Primary Completion Date
September 30, 2022
Completion Date
September 30, 2023
Last Updated
April 26, 2022
36
ESTIMATED participants
Curcumin
DIETARY_SUPPLEMENT
Lead Sponsor
St Mary's University College
NCT06810271
NCT03284450
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions